$EXPO

Corrigan Catherine sold $113K of EXPO

Corrigan Catherine (Chief Executive Officer) sold 1,707 shares of EXPONENT INC (EXPO) at $66.28 ($0.11M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Corrigan Catherine
Published Aug 19, 2026, 1:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 1:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXPO
Neutral
high confidence
Mentioned
$EXPO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXPONeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new company performance, guidance, or regulatory developments.

02

Market read

Traders may note the insider sale, but the 10b5-1 pre-arranged nature makes it more of a monitoring datapoint than a catalyst.

03

What to watch

The article provides only the sale size and plan type, not total insider ownership changes over time, sale frequency, or whether other executives sold concurrently.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-18 after-hours; reflects sale executed 2026-08-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Exponent Inc.

Company-level read

Ticker impact

$EXPONeutralHigh confidence
Context

Exponent CEO Corrigan Catherine sold 1,707 shares in an open-market transaction on 2026-08-17 for about $113.1K, per Form 4.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted.

Evidence & confidence

The filing specifies an open-market sale and that it was pre-arranged under Rule 10b5-1, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced confidence or liquidity needs, which some traders may still front-run.

Key entities

  • Exponent Inc

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • Corrigan Catherine

    Exponent CEO and reporting officer/director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXPOMedAI 8/10

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Exponent, Inc. (EXPO) reported Q2 2026 net revenues of $148.9 million, up 12% from $132.9 million a year earlier, and net income of $29.4 million, up 11%. Diluted EPS was $0.60. Management raised FY 2026 revenue guidance to 9% to 10% growth and EBITDA margin to 27.8% to 28.1%, and authorized an additional $50 million for share repurchases.

$EXPOMedAI 8/10

Exponent Q2 Earnings Call Highlights

Exponent (NASDAQ:EXPO) reported Q2 EBITDA up 16% to $42.7 million, with EBITDA margin at 28.7% of net revenue versus 27.8% a year earlier. Billable hours rose 8% to about 390,000 and utilization increased to 74%. The company repurchased $67.4 million of stock and paid $14.8 million in dividends. It raised 2026 outlook for net revenue growth of 9% to 10%.